Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07738757) titled 'SKB264 Plus KL-A167 in MSI-H/dMMR Advanced Gynecological Malignancies' on July 28.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Peking Union Medical College Hospital
Condition:
Recurrent or Metastatic MSI-H/dMMR Gynecological Malignancies
Intervention:
Drug: Sacituzumab Tirumotecan (Sac-TMT)
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 1, 2026
Target Sample Size: 80
Countries of Recruitment:
China
To know more, visit https...